Introduction {#Sec1}
============

Cystinosis is a rare, metabolic, autosomal recessive, genetic lysosomal storage disorder characterized by an accumulation of cystine in various organs and tissues \[[@CR1], [@CR2]\]. Infantile nephropathic cystinosis is the most common (95% of cases) and severe form of the disease, and is associated with progressive renal failure that can lead to end-stage renal disease by mid-childhood if left untreated \[[@CR1]\].

Cysteamine bitartrate is a cystine-depleting aminothiol agent approved in the United States and Europe in immediate-release and delayed-release (DR) formulations for the treatment of nephropathic cystinosis in children and adults \[[@CR3], [@CR4]\]. Cysteamine bitartrate DR therapy taken consistently at regular intervals has been shown to reduce leukocyte cystine levels, the rate of decline in renal function, and progression to renal failure if initiated early \[[@CR2], [@CR5]--[@CR7]\].

Cysteamine bitartrate DR capsules (Procysbi^®^; Horizon Pharma, Lake Forest, IL, USA) are an enteric-coated formulation designed to prevent premature release of cysteamine in the stomach and thereby increase bioavailability by allowing absorption from the duodenum, where gastrointestinal pH is higher. Studies have shown that cysteamine bitartrate DR is noninferior to the immediate-release formulation in terms of maintaining low leukocyte cystine levels but at a lower total daily dose and reduced dosing frequency \[[@CR8], [@CR9]\]. Cystine levels rise very quickly when therapy is interrupted, and patients frequently have difficulty with adherence because of the drug's potential to cause gastrointestinal irritation. Delaying and sustaining absorption of cysteamine may, therefore, have a beneficial effect on patient adherence, which is a recognized issue with cysteamine therapy \[[@CR2]\].

A previous pharmacokinetic (PK) study determined that optimal absorption of cysteamine bitartrate DR capsules occurs during the fasting state (\> 30 min before a carbohydrate-rich meal) \[[@CR10]\]. It is also recommended that cysteamine bitartrate DR be administered with fruit juice (except grapefruit juice) for maximum absorption \[[@CR4]\]. Omeprazole is a proton pump inhibitor that inhibits gastric acid secretion and, theoretically, may cause the premature release of cysteamine by increasing intragastric pH, thereby affecting the PK of cysteamine bitartrate. A pilot PK evaluation in 20 healthy subjects demonstrated that concomitant omeprazole administration did not significantly affect the primary PK parameters of cysteamine bitartrate DR (data not shown).

As part of a post-marketing commitment to support the new drug application and to inform administration methods, the current study was designed to assess the effects of multiple-dose omeprazole and water or orange juice on cysteamine PK and bioavailability. Specifically, the primary objectives of this study were to compare the key PK parameters of cysteamine bitartrate DR capsules administered with (1) orange juice or (2) water, as well as with (3) multiple oral doses of omeprazole with water, such that omeprazole was at steady state. This study design will confirm whether multiple-dose omeprazole affects the PK and bioavailability of cysteamine when cysteamine bitartrate DR is administered with water instead of orange juice.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Approval for this study was granted by Chesapeake Research Review.

This was an open-label, single-dose, three-period, randomized study in healthy adult subjects. Cysteamine bitartrate DR capsules (Procysbi^®^; Horizon Pharma, Inc., Lake Forest, Illinois, USA) were supplied as 75-mg capsules. Omeprazole was supplied as 20-mg delayed-release capsules (Mylan Pharmaceuticals, Canonsburg, PA, USA). A single branded orange juice (SUNCUP™) was used for all subjects. Any PK effects on cysteamine from PPIs would be expected to be the same with similar acting drugs with similar effects on gastric pH; therefore, no other PPIs were studied. All study drugs were administered orally following an overnight fast, and subjects were instructed not to crush, split, or chew the capsules.

Study Population {#Sec4}
----------------

Healthy adult nonsmokers, including males and females of non-childbearing potential, aged 18--55 years, with a body mass index (BMI) from 18.5 to 32.0 kg/m^2^ at screening, were considered suitable for inclusion. Key exclusion criteria included clinically significant medical/psychiatric conditions or illnesses that might have confounded the results of the study or posed an additional risk to the subject.

Subjects were free to withdraw from the study at any time for any reason, or may have been withdrawn from the study by the principal or subinvestigator for adverse events (AEs), difficulties in blood collection, or protocol violation.

Treatment Protocol {#Sec5}
------------------

Subjects were randomly assigned to receive all of the following treatments (A, B, and C) in one of two sequences over three periods (ABC, BAC; Fig. [1](#Fig1){ref-type="fig"}). Subjects received each treatment on one occasion:Fig. 1Study design.*Treatment A* single dose of cysteamine bitartrate delayed-release capsules (600 mg) with orange juice on day 1.*Treatment B* single dose of cysteamine bitartrate delayed-release capsules (600 mg) with water on day 1.*Treatment C* omeprazole (20 mg) with water once daily for 5 days + single dose of cysteamine bitartrate delayed-release capsules (600 mg) with water on day 5. On each of the 5 days, omeprazole was administered within ± 1 h of the dosing time on day 1 Treatment A: Cysteamine bitartrate 600 mg (8 × 75-mg DR capsules) at hour 0 on day 1 with approximately 240 mL orange juiceTreatment B: Cysteamine bitartrate 600 mg (8 × 75-mg DR capsules) at hour 0 on day 1 with approximately 240 mL waterTreatment C: Omeprazole 20 mg with approximately 240 mL water every 24 h for 5 consecutive days (within ± 1 h of dosing time on day 1), co-administered with cysteamine bitartrate 600 mg at hour 0 on day 5 with approximately 240 mL water.

Additional water and/or orange juice, up to a maximum of 50 mL, was administered if needed by the subject, with capsule dosing completed within 2 min of the scheduled time.

The 600-mg oral dose of cysteamine bitartrate DR was selected for this study as this is the same dose used in previous healthy-subject studies, is well tolerated, and was well below the dose in the US prescribing information. A dose of 20 mg omeprazole daily is within the recommended dose as prescribed in the US labeling \[[@CR11]\]. In addition, multiple doses for 5 consecutive days ensured maximum inhibition of acid secretion by omeprazole, as this pharmacodynamic response reaches a plateau after 4 days of dosing.

Study Procedures {#Sec6}
----------------

On day 1 of period 1, subjects were randomized to one of two treatment sequences: ABC or BAC.

On day 1 of periods 1 and 2, a single oral dose of cysteamine bitartrate DR was administered with orange juice (treatment A) or water (treatment B), followed by blood sampling for 24 h for the determination of plasma cysteamine levels.

In period 3, multiple oral doses of omeprazole with water were administered once daily for 5 consecutive days (days 1--5), co-administered with a single oral dose of cysteamine bitartrate DR with water (treatment C) on day 5. Blood samples for the determination of plasma cysteamine levels were taken for 24 h following cysteamine bitartrate DR dosing on Day 5.

There was a washout period of 2 days between the first dosing in each period. Subjects were followed up approximately 14 days after the last study drug administration to determine whether any AE had occurred since the last dose of study drug(s).

Outcome Measures {#Sec7}
----------------

The following primary PK parameters were assessed: area under the concentration--time curve from time 0 to the time of the last observed/measured non-zero concentration (AUC~0--*t*~), area under the concentration--time curve from time 0 extrapolated to infinity (AUC~0--*∞*~), maximum observed concentration (*C*~max~), and time to reach *C*~max~ (*t*~max~). In addition, the percent of AUC~0--*∞*~ extrapolated (AUC~%extrap~), apparent first-order terminal elimination rate constant (*k*~el~), apparent first-order terminal elimination half-life (*t*~½~), apparent total plasma clearance after extravascular administration (CL/F), and the apparent volume of distribution during the terminal elimination phase after extravascular administration (*V*~z~/*F*) were calculated. All PK parameters were calculated using Phoenix^®^ WinNonlin^®^, v.6.3 from the 24-h plasma cysteamine concentration--time data.

Blood samples for determining plasma cysteamine concentrations were obtained at the following time points: pre-dose (0 h), 0.5, 1, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 18, and 24 h post-dose.

Safety was assessed via evaluation of AEs classified by the Medical Dictionary for Regulatory Activities (MedDRA) v.19.0, physical examination, 12-lead electrocardiograms, vital signs (including systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate), body weight, and clinical laboratory tests. Only treatment-emergent AEs (TEAEs) were summarized.

Statistical Analysis {#Sec8}
--------------------

A sample size of 28 subjects was calculated using a power of at least 80% and an alpha error of 5%. The power was defined as the probability of having a 90% confidence interval (CI) to detect a ratio within the acceptance criteria of 80.00--125.00%. A true ratio between 95% and 105% was assumed, and an intra-subject coefficient of variation (CV) of \~ 25% obtained from previous data was used. A total of 32 subjects were dosed to allow for possible dropouts.

Summary statistics were calculated for all nominal concentration--time points and for plasma cysteamine PK parameters. In addition, geometric means and geometric CVs were calculated for *C*~max~ and AUC parameters.

For PK parameters, analysis of variance was performed on the log-transformed AUC~0--*t*~, AUC~0--*∞*~, and *C*~max~ with sequence and treatment as fixed effects and subject nested within sequence as a random effect. Period was not considered in the statistical model because the third treatment period was confounded with treatment C. The linear model included calculation of least-squares means (LSM), the difference between treatment LSM, and the standard error associated with this difference. Ratios of LSM were calculated using the exponentiation of the difference between treatment LSM from the analyses on the log-transformed AUC~0--*t*~, AUC~0--*∞*~, and *C*~max~. These ratios were expressed as a percentage relative to the appropriate reference treatment (treatment A or treatment B), depending on the comparison of interest. Consistent with the two one-sided tests, 90% CIs for the ratios were derived by exponentiation of the CIs obtained for the difference between treatment LSM resulting from the analyses on the log-transformed AUC~0--*t*~, AUC~0--*∞*~, and *C*~max~, and were expressed as a percentage relative to treatment A or treatment B, depending on the following comparisons of interest:Cysteamine bitartrate DR capsules + water (treatment B) compared with cysteamine bitartrate DR capsules + orange juice (treatment A)Omeprazole + cysteamine bitartrate DR capsules + water (treatment C) compared with cysteamine bitartrate DR capsules + water (treatment B)Omeprazole + cysteamine bitartrate DR capsules + water (treatment C) compared with cysteamine bitartrate DR capsules + orange juice (treatment A).

Nonparametric analysis (Wilcoxon signed rank test) was performed on *t*~max~, which included calculation of median and 95% CIs of the differences among treatments.

All plasma cysteamine concentrations and/or PK parameter descriptive statistics were generated using SAS^®^, v.9.3 (Cary, NC, USA).

Results {#Sec9}
=======

Subject Disposition and Demographics {#Sec10}
------------------------------------

A total of 32 subjects (mean age, 41.7 years \[range, 22--54 years\], mean ± SD BMI 27.6 ± 2.6 kg/m^2^) were randomly assigned equally to treatment sequence 1 (ABC, *n* = 16) or treatment sequence 2 (BAC, *n* = 16), and all subjects completed the study. Baseline characteristics of the overall population and the two treatment sequence populations were similar (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographic characteristicsCharacteristicSequence 1 (ABC)\
*n* = 16Sequence 2 (BAC)\
*n* = 16Overall\
*n* = 32Sex, *n* (%) Female4 (25)5 (31)9 (28) Male12 (75)11 (69)23 (72)Race, *n* (%) American Indian or Alaskan native01 (6)1 (3) Black or African American2 (13)1 (6)3 (9)White14 (88)14 (88)28 (88)Age, years Mean (SD)41.1 (9.9)42.3 (6.4)41.7 (8.3) Median (min--max)41.5 (22--54)44.0 (30--52)43.5 (22--54)BMI, kg/m^2^ Mean (SD)27.8 (2.5)27.4 (2.8)27.6 (2.6) Median (min--max)28.7 (22.2--30.9)27.2 (20.6--31.6)27.7 (20.6--31.6)*BMI* body mass index, *max* maximum, *min* minimum

Plasma Cysteamine Concentrations {#Sec11}
--------------------------------

Linear mean plasma cysteamine concentration--time profiles for treatments A, B, and C are shown in Fig. [2](#Fig2){ref-type="fig"}. The peak mean plasma cysteamine concentration following co-administration of cysteamine bitartrate DR capsules with orange juice (treatment A, 1892 ng/mL) was higher compared with co-administration with water (treatment B, 1663 ng/mL) or co-administration with omeprazole 20 mg and water (treatment C, 1712 ng/mL). Mean times to peak plasma cysteamine concentration were 3.5, 3.0, and 2.5 h post-dose for treatments A, B, and C, respectively (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Mean plasma cysteamine concentration--time profiles.*Treatment A* single dose of cysteamine bitartrate delayed-release capsules (600 mg) with orange juice.*Treatment B* single dose of cysteamine bitartrate delayed-release capsules (600 mg) with water.*Treatment C* omeprazole (20 mg) with water once daily for 5 days + single dose of cysteamine bitartrate delayed-release capsules (600 mg) with water on day 5

Cysteamine Pharmacokinetics {#Sec12}
---------------------------

The *C*~max~ and AUC parameter values indicate similar peak and total exposures to cysteamine when cysteamine bitartrate was administered with water or orange juice, but exposures were slightly higher with co-administration of omeprazole (Table [2](#Tab2){ref-type="table"}). Co-administration with omeprazole and water led to an earlier median *t*~max~ (2.50 h) compared with water alone (3.00 h) or orange juice alone (3.50 h; Table [2](#Tab2){ref-type="table"}).Table 2Pharmacokinetics of cysteamine according to treatment groupParameter^a^Treatment A\
*n* = 32Treatment B\
*n* = 32Treatment C\
*n* = 32AUC~0--*t*~ (ng·h/mL)^a^6724.8 (29.0)6788.4 (28.7)7313.0 (25.8)AUC~0--∞~ (ng·h/mL)^a^6936.3 (28.9)6983.4 (29.0)7522.9 (26.0)*C*~max~ (ng/mL)^a^2169 (35.0)2010 (39.9)2223 (30.4)*t*~max~ (h)^b^3.50 (2.5--6.0)3.00 (2.0--6.0)2.50 (1.0--4.1)*t*~½~ (h)^c^5.79 ± 0.805.95 ± 0.785.99 ± 0.50CL/F (L/h)^c^89.9 ± 25.289.3 ± 24.882.4 ± 21.7V~z~/F (L)^c^746.9 ± 218.9751.7 ± 178.5707.6 ± 183.4*AUC*~*0*-*t*~ area under the concentration--time curve from time 0 to the time of the last observed/measured non-zero concentration, *AUC*~*0*-*∞*~ area under the concentration--time curve from time 0 extrapolated to infinity, *CL/F* apparent clearance, *C*~*max*~ maximum observed concentration, *CV* coefficient of variation, *max* maximum, *min* minimum, *PK* pharmacokinetic, *t*~*½*~ half-life, *t*~*max*~ time to maximum concentration, *V*~*z*~*/F* apparent volume of distribution^a^Geometric mean (geometric %CV)^b^Median (min--max)^c^Mean ± SD

However, other PK parameters, including *t*~½~, CL/*F*, and *V*~z~/*F*, were similar for treatment groups A, B, and C. The ratios of AUC and *C*~max~ between treatment sequences demonstrate that overall exposure to cysteamine was similar when it was administered with either water or orange juice, and when it was administered with omeprazole and either water or orange juice (Table [3](#Tab3){ref-type="table"}). Furthermore, for all comparisons, ratios and 90% CIs were within the 80--125% bioequivalence range for AUC~0--*t*~, AUC~0--*∞*~, and *C*~max~. However, *t*~max~ occurred significantly earlier when cysteamine was administered with water than when it was administered with orange juice (B--A difference − 0.50, 95% CI − 1.00 to 0.00, *P* = 0.0425), earlier with omeprazole than with water only (C--B difference − 0.50, 95% CI − 1.00 to − 0.24, *P* = 0.0017), and earlier with omeprazole than with orange juice only (C--A difference − 1.00, 95% CI − 1.47 to − 0.75, *P* \< 0.0001).Table 3Cysteamine pharmacokinetics: statistical comparisons among treatment groupsWater (B) versus orange juice (A)ParameterTreatment B\
*n* = 32Treatment A\
*n* = 32B/A (%)90% CIAUC~0--*t*~ (ng·h/mL)6788.46724.8100.9595.89--106.27AUC~0--*∞*~ (ng·h/mL)6983.46936.3100.6895.74--105.88*C*~max~ (ng/mL)2010216992.6583.82--102.41Omeprazole (C) versus water only (B)ParameterTreatment C\
*n* = 32Treatment B\
*n* = 32C/B (%)90% CI AUC~0--*t*~ (ng·h/mL)7313.06788.4107.73102.33--113.41 AUC~0--∞~ (ng·h/mL)7522.96983.4107.72102.44--113.29 *C*~max~ (ng/mL)22232010110.60100.06--122.26Omeprazole (C) versus orange juice only (A)ParameterTreatment C\
*n* = 32Treatment A\
*n* = 32C/A (%)90% CI AUC~0--*t*~ (ng·h/mL)7313.06724.8108.75103.30--114.48 AUC~0--*∞*~ (ng·h/mL)7522.96936.3108.46103.13--114.06 *C*~max~ (ng/mL)22232169102.4792.70--113.27*AUC*~*0*-*t*~ area under the concentration--time curve from time 0 to the time of the last observed/measured non-zero concentration, *AUC*~*0*-*∞*~ area under the concentration--time curve from time 0 extrapolated to infinity, *CI* confidence interval, *C*~*max*~ maximum observed concentration

Safety {#Sec13}
------

Overall, no deaths, serious AEs, discontinuations due to AEs, or clinically significant changes in vital signs, clinical laboratory results, or electrocardiography occurred in any subjects. In total, 20 TEAEs were reported by nine (28%) subjects across all treatment periods, and the most common TEAE was diarrhea (five events in four subjects overall; Table [4](#Tab4){ref-type="table"}). In total, ten TEAEs were considered related to cysteamine bitartrate DR, three events related to omeprazole, and two events related to both cysteamine bitartrate DR and omeprazole. All TEAEs were of mild severity, with the exception of one moderate severity headache, which was considered to be related to omeprazole.Table 4Subjects with treatment-emergent adverse events by treatment groupTEAEs, *n* (%)Treatment A\
*n* = 32Treatment B\
*n* = 32Treatment C\
Days 1--4\
*n* = 32Treatment C\
Days 5 +\
*n* = 32Treatment C\
Overall\
*n* = 32Total\
*n* = 32Subjects with TEAEs (% total)7 (22)2 (6)3 (9)2 (6)4 (13)9 (28) Abdominal pain01 (3)0001 (3) Constipation1 (3)00001 (3) Diarrhea4 (13)1 (3)0004 (13) Epigastric discomfort1 (3)00001 (3) Upper respiratory tract infection1 (3)00001 (3) Limb discomfort01 (3)0001 (3) Dizziness1 (3)01 (3)01 (3)2 (6) Dysgeusia0001 (3)1 (3)1 (3) Head discomfort0001 (3)1 (3)1 (3) Headache001 (3)01 (3)1 (3) Presyncope1 (3)0001 (3)1 (3) Micturition disorder001 (3)01 (3)1 (3) Dysmenorrhea01 (3)0001 (3) Throat tightness0001 (3)1 (3)1 (3) Dry skin01 (3)0001 (3)*TEAE* treatment-emergent adverse event

Discussion {#Sec14}
==========

In this study, peak and overall exposures to cysteamine were shown to be statistically equivalent when cysteamine bitartrate DR capsules were administered with orange juice, water, or with omeprazole and water at steady state for cysteamine bitartrate. Further, ratios of key PK parameters were entirely within the 80--125% acceptance range for bioequivalence for all comparisons. The *t*~max~ occurred earlier when cysteamine bitartrate DR capsules were co-administered with omeprazole and water compared with treatment with cysteamine bitartrate DR capsules only (either water or orange juice). All treatments were well tolerated, and the study revealed no additional safety issues.

Suboptimal adherence is a known issue with cysteamine bitartrate formulations. This tendency relates, in part, to the high frequency of dosing, especially with the immediate-release formulation, which requires administration every 6 h \[[@CR2]\]. Cysteamine bitartrate DR capsules, which allow for less frequent dosing, were formulated to release active drug at a pH of 5.5--6.0 in the small intestine \[[@CR12], [@CR13]\]. Studies to date have shown that the PK of both immediate release and DR formulations of cysteamine bitartrate are adversely affected by concomitant food intake. In the case of DR capsules, a high-fat meal substantially reduced exposure (as shown by AUC and *C*~max~) and doubled *t*~max~ compared with fasting administration \[[@CR10]\]. This has justified the recommendation that cysteamine bitartrate be administered in the fasting state and at least 30 min before a carbohydrate-rich meal \[[@CR4]\]. In addition, it has been recommended that cysteamine bitartrate be administered with juice (but not grapefruit juice). Although the results of this study do not substantially alter these recommendations, they do demonstrate that co-administration with water did not adversely affect the bioavailability of cysteamine bitartrate DR. Further, co-administration with omeprazole also did not significantly reduce the overall exposure to cysteamine bitartrate, although the *t*~max~ was reduced significantly compared with administration with water or orange juice only.

The main strengths of this study are the use of randomization and a three-period treatment protocol, with washout periods between each treatment period. The main limitation of this study was the recruitment of healthy adult subjects rather than children with cystinosis, the main demographic group in clinical practice. The sample size was relatively small, but did meet the statistical test for evaluating bioequivalence. The study evaluated the PK of cysteamine in the presence of just one of the available PPIs, but we do not consider this a limitation. Maximal inhibition of acid secretion was achieved with omeprazole 20 mg, so the results would not have differed if additional PPIs had been tested.

Conclusions {#Sec15}
===========

Mean plasma peak and total exposures of cysteamine were similar when cysteamine bitartrate DR capsules were administered with water or orange juice, as well as with and without omeprazole 20 mg once daily for 5 days. The median *t*~max~ was 0.5 h later when cysteamine bitartrate DR capsules were administered with orange juice compared with water and earlier by 0.5 h when administered with omeprazole. However, PK profiles demonstrating exposure were essentially similar for all administration methods.
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